GPhA Names Chester ‘Chip’ Davis Jr. as New President

GPhA has selected Chester “Chip” Davis, Jr., as president and CEO, taking over for Ralph Neas, who is stepping down.

Davis, who is executive vice president for advocacy and member relations at PhRMA, assumes the position at GPhA on Aug. 18.

He has 20 years of experience in the biopharma sector, including a stint overseeing government relations and strategic alliances at AstraZeneca. Davis holds a law degree and serves on the board of the Global Intellectual Property Center. In January, Neas announced he would leave GPhA in the fall. He has served as head of GPhA since the fall of 2011, overseeing everything from the implementation of GDUFA to the development of the biosimilar approval pathway (Generic Line, Feb. 4). — Meg Bryant


$1,097 $847


Subscribe to Generic Line and save $250 off the regular one-year price of $1,097 — plus receive a FREE copy of our webinar, Success Strategies for Biosimilars Approval — a $287 Value!

Key Benefits

LINKS TO KEY DOCUMENTS — Each issue provides you with links that support GEN's articles such as FDA guidances, warning letters, rules, full texts of proposed legislation and more.

FDANEWS DRUG DAILY BULLETIN — This daily email brings you important FDA and international regulatory, legislative and business news in the pharmaceutical industry.

ONLINE ACCESS — Consider our newsletter archive your personal library! Search your current issue — and hundreds of past issues — by keyword and relevancy.